IL-23 promotes tumour incidence and growth
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Chronic inflammation has long been associated with increased incidence of malignancy and similarities in the regulatory mechanisms have been suggested for more than a century. Infiltration of innate immune cells, elevated activities of matrix metalloproteases and increased angiogenesis and vasculature density are a few examples of the similarities between chronic and tumour-associated inflammation. Conversely, the elimination of early malignant lesions by immune surveillance, which relies on the cytotoxic activity of tumour-infiltrating T cells or intra-epithelial lymphocytes, is thought to be rate-limiting for the risk to develop cancer. Here we show a molecular connection between the rise in tumour-associated inflammation and a lack of tumour immune surveillance. Expression of the heterodimeric cytokine interleukin (IL)-23, but not of its close relative IL-12, is increased in human tumours. Expression of these cytokines antagonistically regulates local inflammatory responses in the tumour microenvironment and infiltration of intra-epithelial lymphocytes. Whereas IL-12 promotes infiltration of cytotoxic T cells, IL-23 promotes inflammatory responses such as upregulation of the matrix metalloprotease MMP9, and increases angiogenesis but reduces CD8 T-cell infiltration. Genetic deletion or antibody-mediated elimination of IL-23 leads to increased infiltration of cytotoxic T cells into the transformed tissue, rendering a protective effect against chemically induced carcinogenesis. Finally, transplanted tumours are growth-restricted in hosts depleted for IL-23 or in IL-23-receptor-deficient mice. Although many strategies for immune therapy of cancer attempt to stimulate an immune response against solid tumours, infiltration of effector cells into the tumour tissue often appears to be a critical hurdle. We show that IL-23 is an important molecular link between tumour-promoting pro-inflammatory processes and the failure of the adaptive immune surveillance to infiltrate tumours.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“IL-17 also induces proliferative signaling in keratinocytes through Act1, a major facet of its impact in psoriasis and perhaps also explaining its involvement in skin tumorigenesis”
From The IL-17 Family of Cytokines in Health and Disease (2019) · cites this paper as Langowski et al., 2006
In the citing paper
“this pro-proliferative role likely contributes to the pathogenic effects of IL-17 in psoriasis, as well as potentially in skin cancer”
From The IL-17 Family of Cytokines in Health and Disease (2019) · cites this paper as Langowski et al., 2006
In the citing paper
“In addition, as discussed above, IL-17 promotes proliferation of skin epithelial cells to promote tumorigenesis”
From The IL-17 Family of Cytokines in Health and Disease (2019) · cites this paper as Langowski et al., 2006
Citations
Cites
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
Inflammation and cancer: back to Virchow?
Balkwill, F., & Mantovani, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04046-0 · Cited by 7,746
Harrington, L. E., Hatton, R. D., Mangan, P. R., Turner, H., Murphy, T. L., Murphy, K. M., & Weaver, C. T. (2005) · Nature Immunology · doi:10.1038/ni1254 · Cited by 4,742
IL-23 drives a pathogenic T cell population that induces autoimmune inflammation
Langrish, C. L., Chen, Y., Blumenschein, W. M., Mattson, J., Basham, B., Sedgwick, J. D., McClanahan, T., Kastelein, R. A., & Cua, D. J. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041257 · Cited by 4,099
Self-citationInterleukin-12 and the regulation of innate resistance and adaptive immunity
Trinchieri, G. (2003) · Nature Reviews Immunology · doi:10.1038/nri1001 · Cited by 3,927
The Immunobiology of Cancer Immunosurveillance and Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Immunity · doi:10.1016/j.immuni.2004.07.017 · Cited by 3,032
Cua, D. J., Sherlock, J., Chen, Y., Murphy, C. A., Joyce, B., Seymour, B., Lucian, L., To, W., Kwan, S., Churakova, T., et al. (2003) · Nature · doi:10.1038/nature01355 · Cited by 2,906
Self-citationOppmann, B., Lesley, R., Blom, B., Timans, J. C., Xu, Y., Hunte, B., Vega, F., Yu, N., Wang, J., Singh, K., et al. (2000) · Immunity · doi:10.1016/s1074-7613(00)00070-4 · Cited by 2,822
Self-citationMatrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
Bergers, G., Brekken, R., McMahon, G., Vu, T. H., Itoh, T., Tamaki, K., Tanzawa, K., Thorpe, P., Itohara, S., Werb, Z., et al. (2000) · Nature Cell Biology · doi:10.1038/35036374 · Cited by 2,797
Aggarwal, S., Ghilardi, N., Xie, M.-H., de Sauvage, F. J., & Gurney, A. L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m207577200 · Cited by 1,847
Cited by
Items 201–300 of 1,000
Gordon, K. B., Papp, K. A., Langley, R. G. B., HO, V. C., Kimball, A. B., Guzzo, C. A., Yeilding, N. M., Szapary, P. O., Fakharzadeh, S. S., Li, S., et al. (2011) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2011.06.041 · Cited by 142
“Theoretical risks of pharmacologic blockade of IL-12 and IL-23 include susceptibility to infection(8) and malignancy.(9) Here, we report results of analyses examining the impact of ustekinumab on infection andmalignancywith longer termuse through up to 3 years of treatment.”
BackgroundSwords into plowshares: IL-23 repurposes tumor immune surveillance
Langowski, J. L., Kastelein, R. A., & Oft, M. (2007) · Trends in Immunology · doi:10.1016/j.it.2007.03.006 · Cited by 149
Self-citationChmielewski, M. M., & Abken, H. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1202-z · Cited by 157
Molecular Mechanisms of Mouse Skin Tumor Promotion
Rundhaug, J. E., & Fischer, S. M. (2010) · Cancers · doi:10.3390/cancers2020436 · Cited by 133
“In contrast, cytotoxic CD8+ T cells are found in greater number in the epidermis and dermis of p19 and p40 null mice compared to p35 null and wild-type mice [191].”
BackgroundInfluentialBloch, Y., Bouchareychas, L., Merceron, R., Składanowska, K., Van den Bossche, L., Detry, S., Govindarajan, S., Elewaut, D., Haerynck, F., Dullaers, M., et al. (2018) · Immunity · doi:10.1016/j.immuni.2017.12.008 · Cited by 134
“Furthermore, elevated expression of IL-23 and IL-23R (and IL-17A) has been observed in several cancers, such as those of the skin, lung, breast, and colon (Grivennikov et al., 2012; Langowski et al., 2006; Zhang et al., 2014).”
BackgroundTGF-β Receptor II Loss Promotes Mammary Carcinoma Progression by Th17-Dependent Mechanisms
Novitskiy, S. V., Pickup, M. W., Gorska, A. E., Owens, P., Chytil, A., Aakre, M., Wu, H., Shyr, Y., & Moses, H. L. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0100 · Cited by 136
“The expression of IL-17 was also found to be significantly elevated in human tumors, consistent with activation of IL23-induced processes (35).”
STAT3: A Target to Enhance Antitumor Immune Response
Lee, H., Pal, S. K., Reckamp, K., Figlin, R. A., & Yu, H. (2010) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2010_51 · Cited by 134
“In contrast to its role in promoting inflammatory responses, IL-23 has been implicated in tumor-mediated immunosuppression (Kortylewski et al. 2009c; Langowski et al. 2006).”
BackgroundCellular and molecular mechanisms in cancer immune escape: a comprehensive review
Bhatia, A., & Kumar, Y. (2014) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2014.865519 · Cited by 131
IL-17 in the Pathogenesis of Disease: Good Intentions Gone Awry
Majumder, S., & McGeachy, M. J. (2021) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101819-092536 · Cited by 149
Glas, J., Seiderer, J., Wetzke, M., Konrad, A., Török, H., Schmechel, S., Tonenchi, L., Graßl, C., Dambacher, J., Pfennig, S., et al. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000819 · Cited by 154
“Recent studies demonstrated a critical role for the IL-23/IL-17 pathway in T-cell mediated colitis in different mouse models [21,22,23], in tumour immunity as demonstrated in human tumor tissues and cancer cell lines as well as in knockout mice [24,25], and in the development of autoimmune diseases including autoimmun…”
BackgroundUp for Mischief? IL-17/Th17 in the tumour microenvironment
Maniati, E., Soper, R., & Hagemann, T. (2010) · Oncogene · doi:10.1038/onc.2010.367 · Cited by 141
“Cytokine networks Malignant cells and associated stromal cells, such as fibroblasts and antigen-presenting cells, secrete large amounts of IL-1b, IL-6, IL-23, TNF-a and transforming growth factor-b (TGF-b), which are key cytokines in Th17 differentiation and expansion (Hodge et al., 2005; Balkwill, 2006; Langowski et…”
BackgroundDaisley, B. A., Chanyi, R. M., Abdur-Rashid, K., Al, K. F., Gibbons, S., Chmiel, J. A., Wilcox, H., Reid, G., Anderson, A., Dewar, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18649-5 · Cited by 128
“8 and Supplementary Data 2 and 3) in their cell wall, which can evoke interleukin-23 signaling 43 — a key cytokine thought to contribute to tumorigenesis and progression to metastatic disease in the context of in fl ammation-related cancers 44 .”
The roles and functional mechanisms of interleukin-17 family cytokines in mucosal immunity
Song, X., He, X., Li, X., & Qian, Y. (2016) · Cellular and Molecular Immunology · doi:10.1038/cmi.2015.105 · Cited by 137
NF-κB and STAT3 signaling in glioma: targets for future therapies
Atkinson, G. P., Nozell, S. E., & Benveniste, E. (. N. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.21 · Cited by 126
Opposing Roles for IL-23 and IL-12 in Maintaining Occult Cancer in an Equilibrium State
Teng, M. W. L., Vesely, M. D., Duret, H., McLaughlin, N., Towne, J. E., Schreiber, R. D., & Smyth, M. J. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1337 · Cited by 118
“We (11) and others (10, 25) have recently shown the effect of IL-23 in suppressing both innate and adaptive antitumor effector responses, and we speculate that local tumor infiltrating myeloid cell production of IL-23 and IL-10 quite possibly directly or indirectly suppresses these antitumor activities.”
BackgroundRegulation and pro‐inflammatory function of interleukin‐17 family cytokines
Dong, C. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00709.x · Cited by 125
STAT3 inhibition induces Bax-dependent apoptosis in liver tumor myeloid-derived suppressor cells
Guha, P., Gardell, J., Darpolor, J. K., Cunetta, M., Lima, M., Miller, G., Espat, N. J., Junghans, R. P., & Katz, S. C. (2018) · Oncogene · doi:10.1038/s41388-018-0449-z · Cited by 132
Emerging Understanding of Multiscale Tumor Heterogeneity
Gerdes, M. J., Sood, A., Sevinsky, C., Pris, A. D., Zavodszky, M. I., & Ginty, F. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00366 · Cited by 118
“Moreover, they are important components of angiogenesis, invasion, and metastasis (94), and together with T helper (Th)-2 (95) and Th17 cells (96) can be involved in tumor promotion, progression, or metastasis.”
BackgroundCandida albicans and cancer: Can this yeast induce cancer development or progression?
Ramirez-Garcia, A., Rementeria, A., Aguirre-Urizar, J. M., Moragues, M. D., Antoran, A., Pellon, A., Abad-Diaz-de-Cerio, A., & Hernando, F. L. (2014) · Critical Reviews in Microbiology · doi:10.3109/1040841x.2014.913004 · Cited by 119
“Moreover, this cytokine antagonizes IL-12 and IFN-g, both of which are crucial in Th1-type antitumor immune responses (Langowski et al., 2006, 2007).”
BackgroundOhno, Y., Kitamura, H., Takahashi, N., Ohtake, J., Kaneumi, S., Sumida, K., Homma, S., Kawamura, H., Minagawa, N., Shibasaki, S., et al. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1791-4 · Cited by 134
“IL-12p35 mice are more susceptible to tumor development following exposure to carcinogens compared with wild-type mice [30].”
BackgroundColitis-associated cancer: the role of T cells in tumor development
Waldner, M. J., & Neurath, M. F. (2009) · Seminars in Immunopathology · doi:10.1007/s00281-009-0161-8 · Cited by 143
“IL-23 (upregulation of MMP9 and angiogenesis) [62]”
Roses, R. E., Xu, S., Xu, M., Koldovsky, U., Koski, G. K., & Czerniecki, B. J. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.7.5120 · Cited by 123
“The latter hypothesis is consistent with the observation that IL-23 is over-expressed in some human cancers and induces matrix metalloproteases and angiogenesis in murine models (18).”
BackgroundResultAstrocytes facilitate melanoma brain metastasis via secretion of IL ‐23
Klein, A., Doron, H., Sagi‐Assif, O., Meshel, T., Izraely, S., Ben‐Menachem, S., Bengaiev, R., Ben‐Shmuel, A., Nahmias, C., Couraud, P., et al. (2015) · The Journal of Pathology · doi:10.1002/path.4509 · Cited by 130
“Moreover, IL-23 promotes tumour incidence and growth in a skin cancer model via up-regulation of the matrix metalloproteinase MMP9, increased angiogenesis and reduced CD8+ T cell infiltration [27].”
BackgroundAmedei, A., Munari, F., Bella, C. D., Niccolai, E., Benagiano, M., Bencini, L., Cianchi, F., Farsi, M., Emmi, G., Zanotti, G., et al. (2012) · Internal and Emergency Medicine · doi:10.1007/s11739-012-0867-9 · Cited by 130
“Furthermore, it has been highlighted that IL-23 might represent an important molecular connection between the rise in tumor-associated inflammation and the lack of tumor surveillance by promoting angiogenesis and inflammatory responses, such as up-regulation of MMP-9, but reducing cytotoxic T cell infiltration [38].”
BackgroundCancer-Derived Exosomes as Effectors of Key Inflammation-Related Players
Othman, N., Jamal, R., & Abu, N. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02103 · Cited by 118
What does it mean to be just 17?
Tato, C. M., & O’Shea, J. J. (2006) · Nature · doi:10.1038/441166a · Cited by 159
Induction and stability of human Th17 cells require endogenous NOS2 and cGMP-dependent NO signaling
Obermajer, N., Wong, J. L., Edwards, R. P., Chen, K., Scott, M., Khader, S., Kolls, J. K., Odunsi, K., Billiar, T. R., & Kalinski, P. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20121277 · Cited by 117
The Interleukin‐23 / Interleukin‐17 axis in intestinal inflammation
Maloy, K. J. (2008) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2008.01950.x · Cited by 120
Insights into IL-23 biology: From structure to function
Floss, D. M., Schröder, J., Franke, M., & Scheller, J. (2015) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2015.07.005 · Cited by 126
Epigenetic Regulation of Inflammatory Cytokines and Associated Genes in Human Malignancies
Yasmin, R., Siraj, S., Hassan, A., Khan, A. R., Abbasi, R., & Ahmad, N. (2015) · Mediators of Inflammation · doi:10.1155/2015/201703 · Cited by 116
“It promotes inflammatory responses in the defense against pathogenic infection and upregulation of angiogenic factors and MMPs [78].”
BackgroundMechanisms of Immune Signaling in Colitis-Associated Cancer
Waldner, M. J., & Neurath, M. F. (2015) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2014.11.006 · Cited by 118
ten Berge, J. C., Fazil, Z., van den Born, L. I., Wolfs, R. C. W., Schreurs, M. W. J., Dik, W. A., & Rothova, A. (2019) · Acta Ophthalmologica · doi:10.1111/aos.13899 · Cited by 118
“(Langowski et al. 2006; Teng et al. 2010; Nie et al. 2017) Also in a model of experimental autoimmune uveitis, it was found that IL-23 receptor expressing cd T cells can exert immunesuppressive effects due to their ability to bind IL-23.”
BackgroundA balance of interleukin-12 and -23 in cancer
Ngiow, S. F., Teng, M. W. L., & Smyth, M. J. (2013) · Trends in Immunology · doi:10.1016/j.it.2013.07.004 · Cited by 120
Cytokine regulation networks in the cancer microenvironment
Sheu, B., Chang, W.-C., Cheng, C.-Y., Lin, H., Chang, D.-Y., & Huang, S.-C. (2008) · Frontiers in bioscience · doi:10.2741/3152 · Cited by 117
“A recent report, however, describes a role for IL-23 in promoting tumor incidence and growth (83).”
BackgroundWang, H., Wang, T., Yan, S., Tang, J., Zhang, Y., Wang, L., Xu, H., & Tu, C. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02183-9 · Cited by 133
Tumor metabolism as modulator of immune response and tumor progression
Gottfried, E., Kreutz, M. P., & Mackensen, A. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2012.02.009 · Cited by 127
Progress in Epidermolysis Bullosa Research: Toward Treatment and Cure
Uitto, J., McGrath, J. A., Rodeck, U., Bruckner‐Tuderman, L., & Robinson, E. C. (2010) · Journal of Investigative Dermatology · doi:10.1038/jid.2010.90 · Cited by 125
Munegowda, M. A., Deng, Y., Mulligan, S. J., & Xiang, J. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1054-y · Cited by 126
“Th17 cells and IL-17 expression have been found in various human tumors [6–10].”
BackgroundSpear, P., Barber, A., Rynda-Apple, A., & Sentman, C. L. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103019 · Cited by 111
“In ovarian cancer, Th17 cytokines have been shown to contribute to tumor pathogenesis (55, 56).”
BackgroundMolecular Aspects and Future Perspectives of Cytokine-Based Anti-cancer Immunotherapy
Chulpanova, D. S., Kitaeva, K. V., Green, A. R., Rizvanov, A. A., & Solovyeva, V. V. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00402 · Cited by 114
“On one hand, Th17 cells are able to secrete various cytokines and chemokines, such as IL17, IL23, CCL20 which promote tumor growth (Tartour et al., 1999; Langowski et al., 2006).”
BackgroundThe Interplay between Oxidative Stress, Inflammation and Angiogenesis in Bladder Cancer Development
Wigner, P., Grębowski, R., Bijak, M., Saluk, J., & Szemraj, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094483 · Cited by 127
“(2006) found that the genetic deletion or blockade of IL-23 in mice caused an increased infiltration of cytotoxic T cells with protective effects against cancer [235].”
BackgroundIntestinal inflammation and colorectal cancer: a double-edged sword?
Rizzo, A., Pallone, F., Monteleone, G., & Fantini, M. C. (2011) · PubMed · doi:10.3748/wjg.v17.i26.3092 · Cited by 107
The Microbiome and Cancer: Is the ‘Oncobiome’ Mirage Real?
Thomas, R. M., & Jobin, C. (2015) · Trends in Cancer · doi:10.1016/j.trecan.2015.07.005 · Cited by 110
“These proinflammatory cytokines foster the neoplastic cascade by promoting cellular proliferation and inhibiting apoptosis [164,165].”
BackgroundInteractions between epithelial cells and leukocytes in immunity and tissue homeostasis
Shaykhiev, R., & Bals, R. (2007) · Journal of Leukocyte Biology · doi:10.1189/jlb.0207096 · Cited by 126
Cárdeno, A., Sánchéz‐Hidalgo, M., & Alarcón‐de‐la‐Lastra, C. (2013) · Current Medicinal Chemistry · doi:10.2174/09298673113209990159 · Cited by 119
IRE1α regulates macrophage polarization, PD-L1 expression, and tumor survival
Batista, A., Rodvold, J. J., Su, X., Searles, S. C., Lew, A., Iwawaki, T., Almanza, G., Waller, T. C., Lin, J. H., Jepsen, K., et al. (2020) · PLoS Biology · doi:10.1371/journal.pbio.3000687 · Cited by 132
Th17 cells: positive or negative role in tumor?
Ji, Y., & Zhang, W. (2010) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0849-6 · Cited by 119
“IL-23p19 mRNA was found to be significantly overexpressed in the majority of cancer samples from various organ types, including colon, ovarian, head and neck, lung, and stomach cancers as well as melanoma [95].”
BackgroundBedel, R., Thiery-Vuillemin, A., Grandclément, C., Balland, J., Rémy-Martin, J.-P., Kantelip, B. M., Pallandre, J., Pivot, X. B., Ferrand, C., Tiberghien, P., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-09-4540 · Cited by 113
“Particularly, interleukin 23 (IL-23) was shown to increase tumor incidence in mice (19) and to decrease cancer immunosurveillance through STAT3 (20), which is a transcription factor activated in IBD (21–23) and directly involved both in intestinal inflammation and in cancer progression (24, 25).”
NF-κB: Governing Macrophages in Cancer
Cornice, J., Verzella, D., Arboretto, P., Vecchiotti, D., Capece, D., Zazzeroni, F., & Franzoso, G. (2024) · Genes · doi:10.3390/genes15020197 · Cited by 126
“TAMs respond to the local signals provided by TME depending on tumor type and stage [26–28].”
BackgroundCytokine-based transformation of immune surveillance into tumor-promoting inflammation
Mumm, J. B., & Oft, M. (2008) · Oncogene · doi:10.1038/onc.2008.275 · Cited by 115
“In contrast, deficiency in IL-23 or the IL-23 receptor not only dramatically reduces tumor incidence but also reduces tumor growth of established tumors (Langowski et al., 2006).”
BackgroundInfluentialSelf-citationAlshaker, H. A., & Matalka, K. Z. (2011) · Cancer Cell International · doi:10.1186/1475-2867-11-33 · Cited by 132
“stomach cancers as well as melanoma [88].”
BackgroundPredicting and Preventing Immune Checkpoint Inhibitor Toxicity: Targeting Cytokines
Kang, J. H., Bluestone, J. A., & Young, A. (2021) · Trends in Immunology · doi:10.1016/j.it.2021.02.006 · Cited by 117
Crone, S. G., Skanderup, A. J., Federspiel, B., Bardram, L., Krogh, A., Lund, A. H., & Friis-Hansen, L. J. (2012) · Molecular Cancer · doi:10.1186/1476-4598-11-71 · Cited by 115
“These genes can increase cell proliferation, cell adhesion and angiogenesis [53-55], contribute to tumor lymphangiogenesis [56], activate fibroblasts [57], recruit monocytes to tumors [39,40] and induce tumor-associated macrophages (TAMs) to secrete tumor-promoting mediators [58] (Figure 9).”
BackgroundMatrix metalloproteinases as therapeutic targets in protozoan parasitic infections
Geurts, N., Opdenakker, G., & den Steen, P. E. V. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.11.008 · Cited by 120
Novel strategies exploiting interleukin-12 in cancer immunotherapy
Cirella, A., Luri‐Rey, C., Trani, C. A. D., Teijeira, Á., Olivera, I., Bolaños, E., Álvarez, E. C., Palencia, B., Brocco, D., Fernández-Sendin, M., et al. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108189 · Cited by 109
The role of immunity in elderly cancer
Malaguarnera, L., Cristaldi, E., & Malaguarnera, M. (2009) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2009.06.002 · Cited by 110
“In addition, his cytokine favours a pro-tumor microenvironment [192].”
BackgroundInfluentialDecoding IL-23 Signaling Cascade for New Therapeutic Opportunities
Pastor-Fernández, G., Mariblanca, I. R., & Navarro, M. N. (2020) · Cells · doi:10.3390/cells9092044 · Cited by 109
“For example, IL-23p19-deficient mice are resistant to tumor formation in a cutaneous chemical carcinogenesis model [221,222] and in colorectal cancer mouse models [223].”
BackgroundIFNγ Promotes Papilloma Development by Up-regulating Th17-Associated Inflammation
Xiao, M., Wang, C., Zhang, J., Li, Z., Zhao, X., & Qin, Z. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3479 · Cited by 101
Hu, J., Yuan, X., Belladonna, M. L., Ong, J. M., Wachsmann‐Hogiu, S., Farkas, D. L., Black, K. L., & Yu, J. S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3448 · Cited by 107
“Note: When the present study was finished, Overwijk et al. (37) reported that IL-23 is a potent vaccine adjuvant for the induction of therapeutic, tumor-specific CD8 T-cell response and Bettelli et al. (38) reported that IL-23 is not the differentiation factor for the generation of IL-17-producing T cells, whereas Lan…”
BackgroundPredictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events
Les, I., Martínez, M., Pérez-Francisco, I., Cabero, M., Teijeira, L., Arrazubi, V., Torrego, N., Campillo-Calatayud, A., Elejalde, I., Kochan, G., et al. (2023) · Cancers · doi:10.3390/cancers15051629 · Cited by 100
Ciążyńska, M. A., Olejniczak‐Staruch, I., Sobolewska-Sztychny, D., Narbutt, J., Skibińska, M., & Lesiak, A. (2021) · Life · doi:10.3390/life11040326 · Cited by 115
“Mice with IL-12 ablation (knocked out p35 subunit) showed rapid tumor growth, suggesting that IL-12 has an anti-tumor function [110].”
BackgroundImler, T. J., & Petro, T. M. (2008) · International Immunopharmacology · doi:10.1016/j.intimp.2008.10.015 · Cited by 104
Morgillo, F., Dallio, M., Corte, C. M. D., Gravina, A. G., Viscardi, G., Loguercio, C., Ciardiello, F., & Federico, A. (2018) · Neoplasia · doi:10.1016/j.neo.2018.05.002 · Cited by 106
“[30] Langowski JL, Zhang X, Wu L, Mattson JD, Chen T, Smith K, Basham B,”
BackgroundStrickertsson, J. A. B., Desler, C., Martin-Bertelsen, T., Machado, A. M. D., Wadström, T., Winther, O., Rasmussen, L. J., & Friis-Hansen, L. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063147 · Cited by 108
“In addition, the cytokine IL-23a which promotes tumor incidence and growth [46] and is highly produced in H.”
BackgroundNogueira, M., Warren, R. B., & Torres, T. R. (2020) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16866 · Cited by 98
IL‐23 in the Pathogenesis of Rheumatoid Arthritis
Paradowska‐Gorycka, A., Grzybowska-Kowalczyk, A., Wojtecka-Lukasik, E., & Maśliński, S. (2009) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2009.02361.x · Cited by 98
Animal Models of Colitis‐Associated Carcinogenesis
Kanneganti, M., Mino-Kenudson, M. A., & Mizoguchi, E. (2011) · BioMed Research International · doi:10.1155/2011/342637 · Cited by 111
“IL-23 plays an important role in the inflammatory response against infection, and the expression is increased in IBD [162, 163] and in colon cancer [164].”
BackgroundIL-23-dependent and -independent enhancement pathways of IL-17A production by lactic acid
Yabu, M., Shime, H., Hara, H., Saito, T., Matsumoto, M., Seya, T., Akazawa, T., & Inoue, N. (2010) · International Immunology · doi:10.1093/intimm/dxq455 · Cited by 103
IL-17 Mediated Inflammation Promotes Tumor Growth and Progression in the Skin
He, D., Li, H., Yusuf, N., Elmets, C. A., Athar, M., Katiyar, S. K., & Xu, H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032126 · Cited by 96
“It is postulated that IL-23 mediated up-regulation of IL-17 production is a mechanism [31].”
BackgroundKaiga, T., Sato, M., Kaneda, H., Iwakura, Y., Takayama, T., & Tahara, H. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.12.7571 · Cited by 97
“(24) recently reported that systemic IL-23 administration showed immunological and antitumor effects only as a cancer vaccine adjuvant.”
BackgroundResultHarpaz, N., & Polydorides, A. D. (2010) · Archives of Pathology & Laboratory Medicine · doi:10.5858/134.6.876 · Cited by 105
Mechanism of immune evasion in breast cancer
Wang, M., Zhang, C., Song, Y., Wang, Z., Wang, Y., Fang, L., Xu, Y.-J., Zhao, Y., Wu, Z., & Xu, Y. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s126424 · Cited by 105
“IL-23 can modulate CD8+ T cell infiltration and promote inflammationrelated development in the BC microenvironment.(113) IL-10 can activate both NK cells and CTLs to inhibit development and metastasis of BC cells, and a few researchers have described its negative effect on tumorigenicity.”
A dual role for the immune response in a mouse model of inflammation-associated lung cancer
Dougan, M. L., Li, D., Neuberg, D. S., Mihm, M. C., Googe, P. B., Wong, K., & Dranoff, G. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44796 · Cited by 96
Blockade of IL-23: What is in the Pipeline?
Parigi, T. L., Iacucci, M., & Ghosh, S. (2022) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjab185 · Cited by 93
Mammalian target of rapamycin as a therapeutic target in oncology
Abraham, R. T., & Eng, C. H. (2008) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.12.2.209 · Cited by 99
“It is now recognized that progressive tumor growth is accompanied by alterations in the local host tissue that collectively resemble the chronic response to tissue injury [85] .”
BackgroundOverexpression of the Cellular DEK Protein Promotes Epithelial Transformation In vitro and In vivo
Wise-Draper, T. M., Mintz-Cole, R. A., Morris, T. A., Simpson, D. S., Wikenheiser‐Brokamp, K. A., Currier, M. A., Cripe, T. P., Grosveld, G. C., & Wells, S. I. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2304 · Cited by 92
“A classical two-step epithelial carcinogenesis model was used (30), which consists of a one-time application of DMBA for initiation, followed by TPA promotion twice a week for 20 weeks.”
Emerging role of IL-23/IL-17 axis in H pylori-associated pathology
Caruso, R., Pallone, F., & Monteleone, G. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i42.5547 · Cited by 103
“Additionally, studies in murine models of epithelial cancers have shown that IL-23, but not IL-12, is essential for sustaining the tumor-promoting infl ammatory process and counteracting the ability of cytotoxic CD8+ T cells to infiltrate tumors [ 54 ]”
BackgroundLiu, Y., Song, Y., Lin, D., Lei, L., Mei, Y., Jin, Z., Gong, H., Zhu, Y., Hu, B., Zhang, Y., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.02.050 · Cited by 97
From cancer immunosurveillance to cancer immunotherapy
Stagg, J., Johnstone, R. W., & Smyth, M. J. (2007) · Immunological Reviews · doi:10.1111/j.1600-065x.2007.00566.x · Cited by 107
“Recent studies in mouse models of cancer revealed that IL-23 is a key cytokine governing the balance between pro- and antitumorigenic immune responses (92).”
BackgroundLi, J., Lau, G. K. K., Chen, L., Yuan, Y., Huang, J. C., Luk, J. M., Xie, D., & Guan, X. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046264 · Cited by 90
“For example, mice lacking IL23p19 were resistant to DMBA/TPA-induced skin papilloma [5].”
BackgroundInfluentialChyuan, I., & Lai, J. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.113928 · Cited by 91
Regulation of Natural Killer Cell Function by STAT3
Cacalano, N. A. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00128 · Cited by 95
“STAT3 was shown to be a direct transcriptional activator of the IL-12p19 gene, and IL-23 in the tumor microenvironment inhibited IL-12 production by tumor-associated DCs. STAT3-dependent reciprocal regulation of IL-23 and IL-12 was demonstrated in melanoma (B16), bladder (MB49), and colon (MB38) cancer models and targ…”
BackgroundInfluentialNanoparticle-based drug delivery systems in cancer: A focus on inflammatory pathways
Afshari, A. R., Sanati, M., Mollazadeh, H., Kesharwani, P., Johnston, T. P., & Sahebkar, A. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.01.008 · Cited by 95
The Role of IL-23 in the Pathogenesis and Therapy of Inflammatory Bowel Disease
Korta, A., Kula, J., & Gomułka, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241210172 · Cited by 94
“Furthermore, IL-23 is a strong factor that promotes tumor development, and it is at a higher level in human colorectal tumors [138].”
BackgroundExpression of Th17 Cells in Breast Cancer Tissue and Its Association with Clinical Parameters
Yang, L., Qi, Y., Hu, J., Tang, L., Zhao, S., & Shan, B. (2011) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-011-9276-3 · Cited by 92
Jinushi, M., Hodi, F. S., & Dranoff, G. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00618.x · Cited by 86
“The IL-23/IL-17 axis exerts a dominant role in tumorpromoting inflammation (75, 76).”
BackgroundMahadevan, N. R., & Zanetti, M. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1101531 · Cited by 92
“IL-23 produced by TAM blocks CD8 T cell infiltration into tumors (89) and upregulates Treg differentiation in the tumor miFIGURE 1.”
BackgroundApplications of neural and mesenchymal stem cells in the treatment of gliomas
Kosztowski, T. A., Zaidi, H. A., & Quiñones‐Hinojosa, A. (2009) · Expert Review of Anticancer Therapy · doi:10.1586/era.09.22 · Cited by 93
Connolly, E. C., Saunier, E. F., Quigley, D., Luu, M. T., De Sapio, A., Hann, B., Yingling, J. M., & Akhurst, R. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2941 · Cited by 82
“Il23a, which is known to promote inflammatory tumor progression in the DMBA/PMA model (26), was increased in carcinomas after sustained drug exposure.”
Lactobacillus rhamnosus GG induces tumor regression in mice bearing orthotopic bladder tumors
Seow, S. W., Cai, S., Rahmat, J. N., Bay, B. H., Lee, Y. K., Chan, Y. H., & Mahendran, R. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2009.01426.x · Cited by 78
Kim, B., Yi, E. H., & Ye, S. (2016) · Archives of Pharmacal Research · doi:10.1007/s12272-016-0795-8 · Cited by 87
Saraiva, D. P., Jacinto, A., Borralho, P., Braga, S. A., & Cabral, M. G. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02605 · Cited by 89
“0001) that is pro-inflammatory but can also impair CTLs’ activity through the activation of Tregs (28) (Figure 6).”
BackgroundQian, X., Gu, L., Ning, H., Zhang, Y., Hsueh, E. C., Fu, M., Hu, X., Wei, L., Hoft, D. F., & Liu, J. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1203141 · Cited by 81
“Consistent with a previous report (17), our study confirms that IL-23 was overexpressed in breast tumor tissues.”
BackgroundResultNardin, A. (2008) · Frontiers in Bioscience · doi:10.2741/2944 · Cited by 78
Mima, K., Ogino, S., Nakagawa, S., Sawayama, H., Kinoshita, K., Krashima, R., Ishimoto, T., Imai, K., Iwatsuki, M., Hashimoto, D., et al. (2017) · Surgical Oncology · doi:10.1016/j.suronc.2017.07.011 · Cited by 84
“IL23, which is mainly produced by tumor-associated myeloid cells that are likely to be activated by bacterial products, has been shown to promote colorectal tumor development and progression through the induction of TH17 cells in the microenvironment [75,80,81].”
BackgroundTargeting IL-17A in multiple myeloma: a potential novel therapeutic approach in myeloma
PRABHALA, R. H., Fulciniti, M., Pelluru, D., Rashid, N. U., Nigroiu, A., Nanjappa, P., Pai, C., Lee, S., Prabhala, N., Bandi, R. L., et al. (2015) · Leukemia · doi:10.1038/leu.2015.228 · Cited by 82
“Increased frequency of Th17 cells is also observed in a number of other human malignancies including, ovarian, prostate, renal, and pancreatic carcinomas 26–28 .”
Chronic Inflammation in Skin Malignancies
Tang, L., & Wang, K. (2016) · Journal of Molecular Signaling · doi:10.5334/1750-2187-11-2 · Cited by 86
Multiple functions of pyruvate kinase M2 in various cell types
Lee, Y.-B., Min, J. K., Kim, J., Cap, K. C., Islam, R., Hossain, A. J., Dogsom, O., Hamza, A., Mahmud, S., Choi, D. R., et al. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30536 · Cited by 90
“It has already been well established that p53 induces p21 expression by binding to the p21 promoter (Lanni & Jacks, 1998).”
BackgroundTeymouri, M., Pirro, M., Fallarino, F., Gargaro, M., & Sahebkar, A. (2018) · International Journal of Cancer · doi:10.1002/ijc.31382 · Cited by 77
“Furthermore, tumor growth in mice lacking IL-23 or IL-23R was also decreased compared to the wild type controls.(48) These data suggest that IL-23 may inhibit the immune surveillance activity mediated by cytotoxic T cells, by potentially preventing their ability to infiltrate into the tumor.”
BackgroundWu, B. X., Hong, F., Zhang, Y., Ansa-Addo, E. A., & Li, Z. (2015) · Advances in cancer research · doi:10.1016/bs.acr.2015.09.001 · Cited by 82
“IL23 is overexpressed in a variety of human cancers, including colon cancer (Langowski et al., 2006).”
Background
Metadata
- Authors
- Langowski, J. L., Zhang, X., Wu, L., Mattson, J. D., Chen, T., Smith, K., Basham, B., McClanahan, T., Kastelein, R. A., & Oft, M.
- Corresponding author
- Oft, Martin
- Venue
- Nature
- Published
- 2006-05-10
- Volume
- 442
- Issue
- 7101
- Pages
- 461-465
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1984467626
- Cited by
- 1,018
- References
- 30
- Citations by year
- 2026: 23 · 2025: 18 · 2024: 32 · 2023: 46 · 2022: 42 · 2021: 44 · 2020: 41 · 2019: 52 · 2018: 41 · 2017: 41 · 2016: 41 · 2015: 47 · 2014: 62 · 2013: 72 · 2012: 65
- FWCI
- 24.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- IL-23, tumour-associated inflammation, tumor surveillance, CD8+ T cell infiltration, intraepithelial lymphocytes, tumor microenvironment, angiogenesis, MMP-9, IL-12, chemical carcinogenesis, IL23R, tumor growth, cancer immunotherapy
- MeSH terms
- Animals, Cell Division, Humans, Inflammation, Interleukins, Mice, Inbred C57BL, Neoplasms, Signal Transduction, CD8-Positive T-Lymphocytes, Interleukin-12, Genetic Predisposition to Disease, Mice, Interleukin-23, Interleukin-23 Subunit p19
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.